Jan Keltjens Appointed President & CEO of AngioDynamics
Executive Brings More Than 20 Years of Successful Medical Industry Leadership Experience to the Company
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 21, 2009--AngioDynamics, Inc. (NASDAQ:ANGO) announced its Board of Directors has
appointed Jan Keltjens, an executive with more than 20 years of
successful medical industry leadership experience, President and CEO
effective March 1, 2009. Mr. Keltjens, 51, will succeed Eamonn Hobbs, a
co-founder of AngioDynamics, who has led the company for the past 21
years and will become Vice Chairman of the Board of Directors.
Mr. Keltjens comes to AngioDynamics after serving as President and CEO
of CryoCath Technologies, Inc. since early 2007. The Montreal,
Quebec-based medical technology company is a leader in cryotherapy
products for treating cardiac arrhythmias and was recently acquired by
Medtronic, Inc. Mr. Keltjens previously served in various leadership
positions at Cordis, a Johnson & Johnson company, including his last
position as Worldwide General Manager of Cordis Neurovascular. He first
joined Cordis in 1995 as Vice President and Managing Director
responsible for international manufacturing and distribution operations,
as well as research and development. He was promoted to Vice President
of European Marketing and Vice President of Worldwide Strategic
Marketing for Cordis Cardiology. Before joining Cordis, Mr. Keltjens led
research and development departments at Unilever and was Managing
Director of a group of small high tech companies.
"Jan's appointment is the culmination of an extensive search for the
best candidate to build on the successes of Eamonn's founding leadership
and take us to the next level in the Company's growth and development,"
said AngioDynamics' Chairman of the Board of Directors, Vincent Bucci.
"Eamonn built AngioDynamics into a $200-million enterprise, and we
believe Jan is the right person to take us to the half billion dollar
revenue level and beyond. Jan brings to the Company extensive global
operating and managerial experience, as well as very strong industry
background and a continuous track record of success. The entire Board of
Directors joins me in welcoming Jan to the Company, and we look forward
to working with him."
"AngioDynamics is a very successful company and I look forward to
working with Eamonn, the Board, and the entire team during the
transition," said Mr. Keltjens. "The Company's IRE technology has the
potential to become a game-changing technology addressing significant
unmet clinical needs in the oncology field, and I believe there are many
more opportunities to consistently grow the Access, Peripheral Vascular
and Oncology businesses. At the same time, a strong balance sheet
presents more opportunities for growth through carefully targeted and
well executed acquisitions."
"Jan Keltjens brings to our Company a comprehensive understanding of our
current markets and during his career has even managed an angiographic
catheter product line. I look forward to working with Jan on a smooth
transition of the CEO's responsibilities, as well as refining my ongoing
role with the Company in the development of markets for IRE technology,"
said Mr. Hobbs.
Mr. Keltjens was born and raised in The Netherlands. He holds a masters
degree in physics, with a specialty in low-temperature physics from the
University of Eindhoven.
About AngioDynamics
AngioDynamics, Inc. is a leading provider of innovative medical devices
used by interventional radiologists, surgeons and other physicians for
the minimally invasive treatment of cancer and peripheral vascular
disease. The Company's diverse product line includes market-leading
radiofrequency ablation and irreversible electroporation resection
systems, vascular access products, angiographic products and
accessories, dialysis products, angioplasty products, drainage products,
thrombolytic products, embolization products and venous products. More
information is available at www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All statements
regarding AngioDynamics' expected future financial position, results of
operations, cash flows, business strategy, budgets, projected costs,
capital expenditures, products, competitive positions, growth
opportunities, plans and objectives of management for future operations,
as well as statements that include the words such as "expects,"
"reaffirms," "intends," "anticipates," "plans," "believes," "seeks,"
"estimates," "potential," or variations of such words and similar
expressions, are forward-looking statements. These forward looking
statements are not guarantees of future performance and are subject to
risks and uncertainties. Investors are cautioned that actual events or
results may differ from the Company's expectations. Factors that may
affect the actual results achieved by the Company include, without
limitation, the ability of the Company to develop its existing and new
products, future actions by the FDA or other regulatory agencies,
results of pending or future clinical trials, overall economic
conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, the effects on pricing from group
purchasing organizations and competition, the ability of the Company to
execute its leadership development plan and integrate purchased
businesses, as well as the risk factors listed from time to time in the
SEC filings of AngioDynamics, Inc., including but not limited to its
Annual Report on Form 10-K for the year ended May 31, 2008. The Company
does not assume any obligation to publicly update or revise any
forward-looking statements for any reason.
In the United States, AngioDynamics' NanoKnife IRE System has been
cleared by the FDA for use in the surgical ablation of soft tissue. This
press release may discuss the use of the NanoKnife for specific clinical
indications for which it is not cleared in the United States at this
time.
CONTACT: AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or
EVC Group, Inc.
Doug Sherk, 415-896-2005 (Investor Relations)
dsherk@evcgroup.com
Jenifer Kirtland, 415-896-2005
jkirtland@evcgroup.com (Investor Relations)
or
Chris Gale, 646-201-5431 (Media)
cgale@evcgroup.com
Steve DiMattia, 646-201-5431 (Media)
sdimattia@evcgroup.com
Source: AngioDynamics, Inc.